Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04214288 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

A Phase 2 study of Advanced ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT04214288 is a Phase 2 study of Advanced ER-Positive HER2-Negative Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 240 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04214288, a Phase 2 study of Advanced ER-Positive HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

Conditions Studied

Advanced ER-Positive HER2-Negative Breast Cancer

Interventions

  • DRUG Fulvestrant
  • DRUG AZD9833

Study Locations (20)

Other

  • Research Site - Brasschaat
  • Research Site - Charleroi
  • Research Site - Ghent
  • Research Site - Haine-Saint-Paul
  • Research Site - Leuven
  • Research Site - Libramont-Chevigny
  • Research Site - Namur
  • Research Site - Paris

Quebec

  • Research Site - Greenfield Park
  • Research Site - Montreal
  • Research Site - Montreal

Florida

  • Research Site - Fort Myers
  • Research Site - St. Petersburg

Tennessee

  • Research Site - Chattanooga
  • Research Site - Nashville

Alabama

  • Research Site - Birmingham

California

  • Research Site - Long Beach

Nebraska

  • Research Site - Lincoln

Ohio

  • Research Site - Canton

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2020-04-22
Est. Completion 2026-03-17
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04214288

The ClinicalTrials.gov registry entry for NCT04214288 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced ER-Positive HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.

NCT04214288 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Quebec, Florida.

Frequently Asked Questions

What is clinical trial NCT04214288 about?

NCT04214288 is a clinical study titled "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer". This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

What is the current status of trial NCT04214288?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2020-04-22. Estimated completion is 2026-03-17.

What conditions does trial NCT04214288 study?

This clinical trial studies the following conditions: Advanced ER-Positive HER2-Negative Breast Cancer.

What interventions are being tested in trial NCT04214288?

The interventions under investigation include: Fulvestrant (DRUG), AZD9833 (DRUG).

Who is sponsoring clinical trial NCT04214288?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04214288 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Advanced ER-Positive HER2-Negative Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.